Xiao Xing Jiang

Continent Pharmaceutical Inc. operates as orphan drug company. It develops, manufactures and distributes pharmaceutical products for the treatment of organ fibrosis and other orphan diseases. Its products includes ETUARY and generic drugs. The company was founded on July 3, 2002 and is headquartered in Beijing, China.

Beijing Ancheng Investment Fund Management Co. Ltd. provides asset management services. The private company is based in Beijing, China.

Chongqing Weiqiao Financial Factoring Co., Ltd. provides financing, refactoring, customer credit investigation and evaluation services. It also provides payment settlement, management and collection of account receivable; transfer and underwriting of financial accounts receivable assets services. The company was founded on November 22, 2016 and is headquartered in Chongqing, China.

Beijing Continent Pharmaceutical Co. Ltd. is a commercial-stage biopharmaceutical company committed to the research, development and commercialization of innovative drugs for organ fibrosis for two decades. The firm focuses on idiopathic pulmonary fibrosis (“IPF”) and have gradually broadened therapeutic field and research & development efforts to other areas of organ fibrosis. The company flagship product ETUARY (pirfenidone capsule) was approved in China in 2011 and is among the first three approved drugs for IPF worldwide. The firm has developed a pipeline of additional four innovative drug candidates, and amassed eight-years’ experience of successful commercialization. The company was founded in July 2002 and is headquartered in Beijing, China.